Everything below concerns melanocortin signalling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
=== Deka Base === The Deka Base (デカベース, Deka Bēsu) is the primary headquarters and base of operations of the S.P.D. Earth unit. It is equipped with Base Beams (ベースビーム, Bēsu Bīmu) and houses the Deka Machines. Additionally, the Deka Base can transform into either the Deka Base Crawler (デカベースクローラー, Deka Bēsu Kurōrā), which is equipped with the Crawler Beam (クローラービーム, Kurōrā Bīmu) cannons, or the humanoid Deka Base Robo (デカベースロボ, Deka Bēsu Robo), which is equipped with Finger Missiles (フィンガーミサイル, Fingā Misairu) and Knee Brace Beams (ニーブレスビーム, Nī Buresu Bīmu). Deka Base Robo's finisher is the Volcanic Buster (ヴォルカニック・バスター, Vorukanikku Basutā). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, the Deka Base has been rebuilt and renamed the Neo Deka Base (ネオデカベース, Neo Deka Bēsu). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, the Neo Deka Base has been rebuilt and renamed the Shin Neo Deka Base (シン・ネオデカベース, Shin Neo Deka Bēsu).
== History == Sam Chun Dang Pharm was established on December 29, 1943, to manufacture and sell pharmaceutical products. The company is widely recognized as the first Korean pharmaceutical company to manufacture eye drops. In 1985, SCD constructed a KGMP-certified factory within the Hyannam Pharmaceutical Industrial Complex in Hwaseong, Gyeonggi Province. In 2013, SCD acquired Optus Pharmaceuticals, at the time the leading domestic manufacturer of single-use ophthalmic eye drops. SCD received the European Union Good Manufacturing Practice certification from the UK MHRA in March 2015, and a further EU GMP certificate from Germany's BGV in April 2018, allowing the company to expand into international markets.
== Contents == Like mainstream smoke, sidestream tobacco smoke is made up of many components including carbon monoxide, tar, nicotine, ammonia, benzene, cadmium and 4-aminobiphenyl. Some of the other compounds found in sidestream smoke are: vinylchloride, hydrogen cyanide, arsenic, acrolein, acetaldehyde, formaldehyde, catechol, cresol, hydroquinone, lead, methyl ethyl ketone, nitric oxide, phenol, styrene, toluene, and butane. Exposure to sidestream smoke yields higher concentrations of these compounds as well as increased concentrations of carboxyhemoglobin, nicotine, and cotinine in the blood. When comparing sidestream and mainstream condensate, sidestream has 2–6 times more condensate per gram than mainstream smoke. Due to the incomplete combustion process responsible for the creation of sidestream smoke, there may be exposure to higher concentrations of carcinogens than are typically inhaled directly.
Sources: en.wikipedia.org
=== South American think tanks === Research done by Enrique Mendizabal shows that South American think tanks play various roles depending on their origins, historical development and relations to other policy actors. In this study, Orazio Bellettini from Grupo FARO suggests that they:
The United States has been heavily involved in the conflict since its beginnings, when in the early 1960s the U.S. government encouraged the Colombian military to attack leftist militias in rural Colombia. This was part of the U.S. fight against communism. In October 1959, the United States sent a "Special Survey Team", composed of counterinsurgency experts, to investigate Colombia's internal security situation. In February 1962, a Fort Bragg top-level U.S. Special Warfare team headed by Special Warfare Center commander General William P. Yarborough, visited Colombia for a second survey. In a secret supplement to his report to the Joint Chiefs of Staff, Yarborough encouraged the creation and deployment of a paramilitary force to commit sabotage and terrorist acts against communists:
=== Temperature-sensitive hydrogels === Using glycerolphosphate salts (possessing a single anionic head) without chemical modification or cross-linking, the pH-dependent gelation properties of chitosan (see above) can be converted to temperature-sensitive gelation properties. In the year 2000, Chenite was the first to design the temperature-sensitive chitosan hydrogels drug delivery system using chitosan and β-glycerol phosphate. This new system can remain in the liquid state at room temperature, while becoming gel with increasing temperature above the physiological temperature (37 °C). Phosphate salts cause a particular behaviour in chitosan solutions, thereby allowing these solutions to remain soluble in the physiological pH range (pH 7), and they will be gel only at body temperature. When the liquid solution of chitosan-glycerol phosphate, containing the drug, enters the body through a syringe injection, it becomes a water-insoluble gel at 37 °C. The entrapped drug particles between the hydrogel chains will be gradually released.
Sources: en.wikipedia.org
Brother Zachariah — formerly known as James "Jem" Carstairs, a Silent Brother, and the former parabatai of Will Herondale, who acts as a kind of uncle to James, Lucie and the others. He is also a first cousin to Cordelia and Alastair. Barbara Lightwood — The eldest child of Gideon Lightwood and Sophie Collins. Growing up, Barbara had the perfect Sight, the ability to see past glamours. She has an understanding with Oliver Hayward, whose family runs the York Institute. Barbara was very affectionate and protective over Thomas—to the point where he found it smothering—and was often considered more gentle than her sister. She was somewhat of a romantic, and wanted to become a dutiful wife rather than a strong Shadowhunter. During a demon attack in Regents Park, Barbara was bitten and collapsed. In her final moments, she was delirious and lashed out, clawing at Oliver who had been crying by her bedside. This unknowingly spread the infection to Oliver who fell ill and died shortly after. Thomas and the others dedicated themselves to not only making a cure but finding and putting an end to the demon attacks in her name. Eugenia Lightwood — The second child of Gideon Lightwood and Sophie Collins. Like Barbara, Eugenia was very affectionate and protective over Thomas, to the point where he found it smothering, and wants to become a dutiful wife rather than a strong Shadowhunter. She is considered stubborn and rebellious. Eugenia was seemingly dubbed "ruined" as she had apparently been found alone with a gentleman whom did not later propose to her.
The synoptic condition for the Tehuantepecer, a violent mountain-gap wind in between the mountains of Mexico and Guatemala, is associated with high-pressure system forming in Sierra Madre of Mexico in the wake of an advancing cold front, which causes winds to accelerate through the Isthmus of Tehuantepec. Tehuantepecers primarily occur during the cold season months for the region in the wake of cold fronts, between October and February, with a summer maximum in July caused by the westward extension of the Azores-Bermuda high pressure system. Wind magnitude is greater during El Niño years than during La Niña years, due to the more frequent cold frontal incursions during El Niño winters. Tehuantepec winds reach 20 knots (40 km/h) to 45 knots (80 km/h), and on rare occasions 100 knots (190 km/h). The wind's direction is from the north to north-northeast. It leads to a localized acceleration of the trade winds in the region, and can enhance thunderstorm activity when it interacts with the Intertropical Convergence Zone. The effects can last from a few hours to six days. Between 1942 and 1957, La Niña had an impact that caused isotope changes in the plants of Baja California, and that had helped scientists to study his impact.
== Difficulty of separation == Unlike plutonium, minor actinides, fission products, or activation products, chemical processes cannot separate 236U from 238U, 235U, 232U or other uranium isotopes. It is even difficult to remove with isotopic separation, as low enrichment will concentrate not only the desirable 235U and 233U but the undesirable 236U, 234U and 232U. On the other hand, 236U in the environment cannot separate from 238U and concentrate separately, which limits its radiation hazard in any one place.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.